We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
Cap. Flow
-$9.09M
Cap. Flow %
-4.16%
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$4.26M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.35M
4
SAGE
Sage Therapeutics
SAGE
+$3.05M
5
SNY icon
Sanofi
SNY
+$2.95M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.92M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.66M
3
ENSG icon
The Ensign Group
ENSG
+$5.27M
4
ARRY
Array Biopharma Inc
ARRY
+$4.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.72M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
2 Real Estate 11.35%
3 Industrials 8.34%
4 Miscellaneous 6.63%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
51
DELISTED
Epizyme, Inc
EPZM
$643K 0.29%
47,449
-10,000
-17% -$156K
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$640K 0.29%
18,029
– –
AFMD
53
DELISTED
Affimed
AFMD
$638K 0.29%
38,686
– –
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
$624K 0.29%
13,800
-4,000
-22% -$182K
FOMX
55
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$539K 0.25%
107,500
– –
MLNT
56
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$488K 0.22%
15,367
– –
IIN
57
DELISTED
IntriCon Corporation
IIN
$484K 0.22%
+12,000
New +$360K
ZGNX
58
CALL
DELISTED
Zogenix, Inc.
ZGNX
$442K 0.2%
+10,000
New +$412K
QCP
59
CALL
DELISTED
Quality Care Properties, Inc.
QCP
$430K 0.2%
+20,000
New +$422K
MODN
60
DELISTED
MODEL N, INC.
MODN
$418K 0.19%
+22,461
New +$396K
DVAX
61
DELISTED
Dynavax Technologies
DVAX
$412K 0.19%
27,000
-3,000
-10% -$51.9K
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$407K 0.19%
149,100
– –
CDMO
63
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$394K 0.18%
+100,402
New +$348K
SPNE
64
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$390K 0.18%
30,899
– –
CYAD
65
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$382K 0.17%
+12,840
New +$394K
DCPH
66
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$375K 0.17%
9,536
-75,554
-89% -$2.22M
IRMD icon
67
iRadimed
IRMD
$1.11B
$365K 0.17%
17,608
-33,451
-66% -$591K
MGLN
68
DELISTED
Magellan Health Services, Inc.
MGLN
$288K 0.13%
3,000
-6,282
-68% -$602K
DERM
69
DELISTED
Dermira, Inc.
DERM
$184K 0.08%
20,018
– –
CFMS
70
DELISTED
Conformis, Inc. Common Stock
CFMS
$159K 0.07%
+5,074
New +$175K
GLMD icon
71
Galmed Pharmaceuticals
GLMD
$4.34M
$119K 0.05%
+7
New +$81.1K
QCP
72
PUT
DELISTED
Quality Care Properties, Inc.
QCP
$38.7K 0.02%
+1,800
New +$38K
ALGN icon
73
Align Technology
ALGN
$11.2B
– –
-3,000
Closed -$753K
MDXG icon
74
CALL
MiMedx Group
MDXG
$656M
– –
-48,000
Closed -$335K
NGNE icon
75
Neurogene
NGNE
$732M
– –
-1,599
Closed -$450K
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.

  • Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
  • Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
  • Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
  • Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
  • Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
  • Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
  • Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.

Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.